Selinexor for advanced hematologic malignancies.

Leukemia & Lymphoma
Janek S WalkerRosa Lapalombella

Abstract

Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inhibit the essential regulatory functions of XPO1 in the eukaryotic cell and have been extensively studied in pre-clinical and clinical tumor models. Recently, selinexor (XPOVIO™), a first-in-class oral SINE molecule, was granted accelerated approval by the United States FDA for penta-refractory multiple myeloma. To establish a complete profile of this emerging drug candidate, this article reviews evidence collected from recent clinical studies against both solid and liquid tumors, describing selinexor as a promising new anti-cancer pharmaceutic against late-stage and highly aggressive tumors. With management of well-defined and predictable adverse effects, selinexor can be a life-saving therapeutic option in cancer patients with few alternatives.

References

Aug 1, 1996·British Journal of Cancer·E S NewlandsM H Brampton
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·N KudoS Horinouchi
Jan 17, 2002·Results and Problems in Cell Differentiation·Maarten Fornerod, Mutsuhito Ohno
Apr 8, 2003·Applied Microbiology and Biotechnology·A BurzlaffT Scheper
Aug 18, 2004·Protein Engineering, Design & Selection : PEDS·Tanja la CourSøren Brunak
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnJoseph M Connors
May 18, 2007·Annual Review of Biochemistry·Atlanta CookElena Conti
Jan 17, 2009·Cancer Research·Sarah C MutkaSumati Murli
Apr 3, 2009·Nature Structural & Molecular Biology·Xiuhua DongYuh Min Chook
Jan 3, 2012·Biochemical Pharmacology·Joel G TurnerDaniel M Sullivan
Jun 9, 2012·Blood·Parvathi RanganathanRamiro Garzon
Jul 27, 2012·Molecular Biology of the Cell·Darui XuYuh Min Chook
Feb 14, 2013·Haematologica·Asfar S AzmiRamzi M Mohammad
Apr 9, 2013·Blood·Kensuke KojimaMichael Andreeff
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Mar 19, 2014·Seminars in Cancer Biology·Joel G TurnerDaniel M Sullivan
Jun 20, 2014·British Journal of Cancer·H SunH P Koeffler
Jul 18, 2014·Cancer Chemotherapy and Pharmacology·Yun ZhengH Phillip Koeffler

❮ Previous
Next ❯

Citations

Nov 28, 2020·Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms·Shalini Guha, Sukesh R Bhaumik
Jan 17, 2021·Journal of Hematology & Oncology·Janek S WalkerRosa Lapalombella

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.